Anti-fgfr4 antibodies and methods of use

43:

• The nucleic acid of claim 42, wherein the antibody further comprises a light chain variable domain framework sequence of SEQ ID NO:
• 9, 10, 11 and/or 12.

44:

• The nucleic acid of claim 42, wherein the antibody further comprises a heavy chain variable domain framework sequence of SEQ ID NO:
• 12, 14, 15 and/or 16.

45:

• The nucleic acid of claim 42, wherein the heavy chain variable domain sequence comprises the amino acid sequence of SEQ ID NO:
• 7 or the light chain variable domain sequence comprises the amino acid sequence of SEQ ID NO:
• 8.

46:

• The nucleic acid of claim 42, wherein the nucleic acid encoding the heavy chain variable domain or light chain variable domain is on a separate vector from a nucleic acid encoding the corresponding light chain variable domain or heavy chain variable domain.

47:

• The nucleic acid of claim 42, wherein the nucleic acid encoding the heavy chain variable domain or light chain variable domain and a nucleic acid encoding the corresponding light chain variable domain or heavy chain variable domain are on a single vector.

48:

• The nucleic acid of claim 42, wherein the nucleic acid encodes the heavy chain variable domain and the light chain variable domain.

49:

• The nucleic acid of claim 42, wherein the heavy chain variable domain sequence comprises the amino acid sequence of SEQ ID NO:7 and the light chain variable domain comprises the amino acid sequence of SEQ ID NO:
• 8.

50:

• The nucleic acid of claim 49, wherein the nucleic acid encoding the heavy chain variable domain or light chain variable domain is on a separate vector from a nucleic acid encoding the corresponding light chain variable domain or heavy chain variable domain.

51:

• The nucleic acid of claim 49, wherein the nucleic acid encoding the heavy chain variable domain or light chain variable domain and a nucleic acid encoding the corresponding light chain variable domain or heavy chain variable domain are on a single vector.

52:

• The nucleic acid of claim 42, wherein said antibody is a full length IgG1 antibody.

53:

• The nucleic acid of claim 49, wherein said antibody is a full length IgG1 antibody.

54:

• A vector comprising the nucleic acid of claim 42.

55:

• A vector comprising the nucleic acid of claim 46.

56:

• A vector comprising the nucleic acid of claim 48.

57:

• A vector comprising the nucleic acid of claim 49.

58:

• A vector comprising the nucleic acid of claim 50.

59:

• An isolated recombinant host cell transformed with the nucleic acid of claim 42.

60:

• An isolated recombinant host cell transformed with the nucleic acid of claim 46.

61:

• An isolated recombinant host cell transformed with the nucleic acid of claim 48.

62:

• An isolated recombinant host cell transformed with the nucleic acid of claim 49.

63:

• An isolated recombinant host cell transformed with the nucleic acid of claim 50.

64:

• An isolated recombinant host cell transformed with the vector of claim 54.

65:

• An isolated recombinant host cell transformed with the vector of claim 58.

67:

• The method of claim 66, wherein the heavy chain variable domain sequence comprises the amino acid sequence of SEQ ID NO:
• 7 and the light chain variable domain sequence comprises the amino acid sequence of SEQ ID NO:
• 8.

69:

• The method of claim 68, wherein the heavy chain variable domain sequence comprises the amino acid sequence of SEQ ID NO:
• 7 and the light chain variable domain sequence comprises the amino acid sequence of SEQ ID NO:
• 8.